Journal Mobile Options
Table of Contents
Vol. 10, No. 4, 1999
Issue release date: July–August 1999
Dement Geriatr Cogn Disord 1999;10:289–294
(DOI:10.1159/000017134)

A Double-Blind, Placebo-Controlled Study of Tacrine in Chinese Patients with Alzheimer’s Disease

Wong W.-J. · Liu H.-C. · Fuh J.-L. · Wang S.-J. · Hsu L.-C. · Wang P.-N. · Sheng W.-Y.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The purpose of the study was to evaluate the efficacy and safety of tacrine over 30 weeks in Chinese patients with probable Alzheimer’s disease (AD). A total of 100 patients with mild to moderate AD were recruited and randomly assigned to active or placebo treatment. The active group received 30 mg/day of tacrine for the first 6 weeks, 60 mg/day for the next 6 weeks, 90 mg/day for 6 more weeks and then 120 mg/day for the remaining 12 weeks. Safety evaluations included biweekly determinations of alanine aminotransferase (ALT). The primary outcome measures were Cognitive Abilities Screening Instrument (CASI), Clinical Global Impression of Change (CGIC) by investigator and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Secondary outcome measures were Mini-mental State Examination (MMSE), Alzheimer’s Deficit Scale (ADS) and CGIC by caregivers. Sixty-eight patients were included in an intent-to-treat analysis (48 active and 20 placebo); 56 patients had evaluable data at week 30 (36 active and 20 placebo). The results of the complete case analysis revealed a significant improvement in the CASI and MMSE scores of the active group in the 18th week (90 mg/day) and the 30th week (120 mg/day) (p < 0.01). In the intent-to-treat analysis, significant improvement of the active group was noted on CASI at week 30 (p = 0.05), but there was no significant difference in the measures of IQCODE, CGIC and ADS. The primary reasons for withdrawal of tacrine-treated patients (39 patients, 52%) were asymptomatic ALT elevation, anorexia and nausea/vomiting. These patients all recovered from the adverse events on discontinuation of treatment. Tacrine produced a statistically significant improvement in the CASI and MMSE in Chinese patients with mild to moderate AD using a lower dose than in western people.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Katzman R: Alzheimer’s disease. N Engl J Med 1986;314:964–973.
  2. Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL: Prevalence of dementia in an urban area in Taiwan. J Formos Med Asssoc 1996;95:762–768.
  3. Liu HC, Lin KN, Teng EL, Wang SJ, Fuh JL et al: Prevalence and subtypes of dementia in Taiwan: A community survey of 5297 individuals. J Am Geriatr Soc 1995;43:144–149.
  4. Yip PK, Shyu TI, Lee JY, et al: Prevalence of dementia in the elderly in an urban district of Taipei. Acta Neurol Sin 1992;1:347–354.
  5. Davies P, Moloney AJF: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;ii:1043.
  6. Dartus RT, Dean RT III, Deer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–417.
  7. Davis KL, Mohs RC: Enhancement of memory processes in Alzheimer’s disease with multiple dose intravenous physostigmine. Am J Psychiatry 1982;139:1421–1424.

    External Resources

  8. Mohs RC, Davis BM, Johns CA, et al: Oral physostigmine treatment of patients with Alzheimer’s disease. Am J Psychiatry 1985;142:28–33.

    External Resources

  9. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A: Oral tetrahydro-aminoacridine in long-term treatment of senile dementia, Alzheimer’s type. N Engl J Med 1988;315:1241–1245.
  10. Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer’s disease. Lancet 1991;337:989–992.
  11. Davis KL, Thal LJ, Gamzu ER, et al and the Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992;327:1253–1259.
  12. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study Group: A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992;268:2523–2529.
  13. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994;13:985–991.

    External Resources

  14. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992–998.
  15. Mckhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: Reports of the NINCDS-ARDRA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  16. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’ a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  17. Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, et al: The Cognitive Abilities Screening Instrument (CASI): A practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994;6:45–56.
  18. Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–1022.
  19. Liu HC, Chou P, Lin KN, Wang SJ, Fuh JL, et al: Assessing cognitive abilities and dementia in a predominantly illiterate population of older individuals in Kinmen. Psychol Med 1994;24:763–767.
  20. Summers WK, DeBoynton V, Marsh GM, Majovski LV: Comparison of seven psychometric instruments used for evaluation of treatment effect in Alzheimer’s dementia. Neuroepidemiology 1990;9:193–207.
  21. Salmon DP, Thal LJ, Butters N, Heindel WC: Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examination. Neurology 1990;40:1225–1230.
  22. Becker JT, Huff FJ, Nebes RD, Holland A, Boller F: Neuropsychological function in Alzheimer’ disease: Pattern of impairment and rate of progression. Arch Neurol 1988;45:263–268.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50